JP2018127458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018127458A5 JP2018127458A5 JP2018039593A JP2018039593A JP2018127458A5 JP 2018127458 A5 JP2018127458 A5 JP 2018127458A5 JP 2018039593 A JP2018039593 A JP 2018039593A JP 2018039593 A JP2018039593 A JP 2018039593A JP 2018127458 A5 JP2018127458 A5 JP 2018127458A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition
- fragment
- protein
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 50
- 102000036639 antigens Human genes 0.000 claims 43
- 108091007433 antigens Proteins 0.000 claims 43
- 239000000203 mixture Substances 0.000 claims 33
- 239000012634 fragment Substances 0.000 claims 24
- 210000003743 erythrocyte Anatomy 0.000 claims 14
- 230000002163 immunogen Effects 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 7
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 6
- 108010061711 Gliadin Proteins 0.000 claims 6
- 102000047918 Myelin Basic Human genes 0.000 claims 6
- 101710107068 Myelin basic protein Proteins 0.000 claims 6
- 230000003614 tolerogenic effect Effects 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 102000016202 Proteolipids Human genes 0.000 claims 5
- 108010010974 Proteolipids Proteins 0.000 claims 5
- 108010076181 Proinsulin Proteins 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 206010022498 insulinoma Diseases 0.000 claims 4
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 4
- 102000006386 Myelin Proteins Human genes 0.000 claims 3
- 108010083674 Myelin Proteins Proteins 0.000 claims 3
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000005012 myelin Anatomy 0.000 claims 3
- 210000004248 oligodendroglia Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 claims 2
- 108010068370 Glutens Proteins 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 108010024847 glutamate decarboxylase 1 Proteins 0.000 claims 2
- 108010050792 glutenin Proteins 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 108010066381 preproinsulin Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 101710087459 Gamma-gliadin Proteins 0.000 claims 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 claims 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 claims 1
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 claims 1
- 101710172364 Glucose-6-phosphatase 2 Proteins 0.000 claims 1
- 102000028180 Glycophorins Human genes 0.000 claims 1
- 108091005250 Glycophorins Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102000055324 Myelin Proteolipid Human genes 0.000 claims 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 108060006613 prolamin Proteins 0.000 claims 1
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/397,202 | 2012-02-15 | ||
| US13/397,202 US9517257B2 (en) | 2010-08-10 | 2012-02-15 | Erythrocyte-binding therapeutics |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557135A Division JP6692602B2 (ja) | 2012-02-15 | 2013-02-15 | 赤血球結合治療剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020100620A Division JP2020147591A (ja) | 2012-02-15 | 2020-06-10 | 赤血球結合治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018127458A JP2018127458A (ja) | 2018-08-16 |
| JP2018127458A5 true JP2018127458A5 (enExample) | 2018-11-22 |
| JP6716619B2 JP6716619B2 (ja) | 2020-07-01 |
Family
ID=48326347
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557135A Active JP6692602B2 (ja) | 2012-02-15 | 2013-02-15 | 赤血球結合治療剤 |
| JP2018039593A Active JP6716619B2 (ja) | 2012-02-15 | 2018-03-06 | 赤血球結合治療剤 |
| JP2020100620A Pending JP2020147591A (ja) | 2012-02-15 | 2020-06-10 | 赤血球結合治療剤 |
| JP2022147649A Pending JP2022184955A (ja) | 2012-02-15 | 2022-09-16 | 赤血球結合治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557135A Active JP6692602B2 (ja) | 2012-02-15 | 2013-02-15 | 赤血球結合治療剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020100620A Pending JP2020147591A (ja) | 2012-02-15 | 2020-06-10 | 赤血球結合治療剤 |
| JP2022147649A Pending JP2022184955A (ja) | 2012-02-15 | 2022-09-16 | 赤血球結合治療剤 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2814500B1 (enExample) |
| JP (4) | JP6692602B2 (enExample) |
| KR (1) | KR20150010699A (enExample) |
| CN (3) | CN104271148A (enExample) |
| AU (2) | AU2013220079B2 (enExample) |
| BR (1) | BR112014020304A8 (enExample) |
| CA (1) | CA2864432A1 (enExample) |
| EA (2) | EA035931B1 (enExample) |
| ES (1) | ES2781773T3 (enExample) |
| HK (1) | HK1202051A1 (enExample) |
| IL (1) | IL234056B (enExample) |
| MX (1) | MX2014009900A (enExample) |
| NZ (2) | NZ628851A (enExample) |
| SG (2) | SG11201404943PA (enExample) |
| WO (1) | WO2013121296A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2657480T3 (es) | 2006-08-11 | 2018-03-05 | Life Sciences Research Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| WO2009101205A2 (en) | 2008-02-14 | 2009-08-20 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| EP2603520A4 (en) | 2010-08-10 | 2014-02-19 | Ecole Polytech | ERYTHROCYTE BINDING THERAPEUTICS |
| HUE055070T2 (hu) | 2010-11-25 | 2021-10-28 | Imnate Sarl | Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra |
| CN105051060A (zh) * | 2013-01-18 | 2015-11-11 | 葛莱高托普有限公司 | 用于增强蛋白质表达的融合肽 |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| JP6702866B2 (ja) | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス， インコーポレイテッド | 合成膜−レシーバー複合体 |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| PT3125927T (pt) | 2014-04-01 | 2021-04-30 | Rubius Therapeutics Inc | Métodos e composições para imunomodulação |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) * | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| AU2016325073B2 (en) * | 2015-09-19 | 2023-03-16 | Ecole Polytechnique Federale De Lausanne (Epfl) | Glycotargeting therapeutics |
| AU2016328582B2 (en) | 2015-09-25 | 2022-11-24 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| CN108289955A (zh) * | 2015-10-23 | 2018-07-17 | 混合生物制药有限公司 | 用于治疗癌症的方法和相关组合物 |
| CN108778318B (zh) | 2016-01-14 | 2022-05-03 | 北卡罗莱纳州立大学 | 葡萄糖响应性胰岛素递送组合物和方法 |
| US11485768B2 (en) | 2016-04-19 | 2022-11-01 | Imcyse Sa | Immunogenic CD1d binding peptides |
| KR102430856B1 (ko) * | 2016-05-03 | 2022-08-08 | 에스큐지 바이오테크놀로지스 컴퍼니 | 관용을 유도하는 생체분자의 세포내 전달 |
| RU2018147235A (ru) | 2016-06-02 | 2020-07-10 | Санофи | Конъюгаты фармацевтического средства и фрагмента, способного связываться с глюкозочувствительным белком |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| KR20250054124A (ko) * | 2017-10-20 | 2025-04-22 | 시에스엘 리미티드 | 방법 |
| JP2021504402A (ja) | 2017-12-01 | 2021-02-15 | サノフイＳａｎｏｆｉ | 薬剤とグルコース感知タンパク質に結合し得る部分との新規のコンジュゲート |
| EP3790901A1 (en) * | 2018-05-07 | 2021-03-17 | Anokion SA | Glycophorin a antigen-binding proteins |
| US12383617B2 (en) | 2018-05-09 | 2025-08-12 | The University Of Chicago | Compositions and methods concerning immune tolerance |
| EP4058049A1 (en) | 2019-11-11 | 2022-09-21 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| WO2021222772A2 (en) * | 2020-05-01 | 2021-11-04 | The Johns Hopkins University | Compositions and methods for coronavirus detection |
| CA3195512A1 (en) | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| EP4373517A1 (en) * | 2021-06-17 | 2024-05-29 | Phaim Pharma Ltd | Individualized cell therapy using patient-derived antigen-specific regulatory t cells |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| CN116731962B (zh) * | 2023-08-14 | 2023-11-03 | 天津中新科炬生物制药股份有限公司 | 全血中分离红细胞的试剂盒及方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358857A (en) | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| US5227293A (en) | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
| US5227165A (en) | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| CA2183535A1 (en) * | 1994-02-28 | 1995-08-31 | Ronald P. Taylor | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
| US6512103B1 (en) | 1995-12-08 | 2003-01-28 | Schering Corporation | Mammalian chemokine reagents |
| EP0930874A2 (en) | 1996-10-09 | 1999-07-28 | Takeda Chemical Industries, Ltd. | A method for producing a microparticle |
| US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| US5948639A (en) | 1997-04-10 | 1999-09-07 | Millennium Pharmaceuticals, Inc. | TGF-β pathway genes |
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| WO1999046392A1 (en) | 1998-03-12 | 1999-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| US6224794B1 (en) | 1998-05-06 | 2001-05-01 | Angiotech Pharmaceuticals, Inc. | Methods for microsphere production |
| EP1087998A1 (en) | 1998-06-16 | 2001-04-04 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| CA2657302A1 (en) | 1998-10-07 | 2000-04-13 | Hermann Oppermann | Modified tgf-.beta. superfamily proteins |
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| GB0019302D0 (en) | 2000-08-08 | 2000-09-27 | Univ Nottingham Trent | Biological materials and the use thereof for the treatment of disease |
| US7470420B2 (en) | 2000-12-05 | 2008-12-30 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts |
| US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| WO2003035105A2 (en) | 2001-10-23 | 2003-05-01 | Centre For Translational Research In Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
| WO2005051174A2 (en) | 2003-11-21 | 2005-06-09 | The Trustees Of Columbia University In The City Of New York | Nucleic acid aptamer-based compositions and methods |
| US8617819B2 (en) | 2004-09-17 | 2013-12-31 | Massachusetts Institute Of Technology | Polymers for analyte detection |
| US7811809B2 (en) | 2005-06-15 | 2010-10-12 | Saint Louis University | Molecular biosensors for use in competition assays |
| US7892734B2 (en) | 2005-08-11 | 2011-02-22 | The Board Of Trustees Of The University Of Illinois | Aptamer based colorimetric sensor systems |
| US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
| EP2160401B1 (en) | 2007-05-11 | 2014-09-24 | Altor BioScience Corporation | Fusion molecules and il-15 variants |
| US8852640B2 (en) | 2008-07-03 | 2014-10-07 | Ecole Polytechnique Federale De Lausanne (Epfl) | Micelles for delivery of nitric oxide |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| US8268977B2 (en) | 2008-11-20 | 2012-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Strongly quenching oligomeric excimer/quencher pairs for detection schemes |
| DK2493487T3 (en) | 2009-10-27 | 2016-12-05 | Erytech Pharma | Composition for induction of specific immunological tolerance |
| EP2603520A4 (en) * | 2010-08-10 | 2014-02-19 | Ecole Polytech | ERYTHROCYTE BINDING THERAPEUTICS |
| US9517257B2 (en) * | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
-
2013
- 2013-02-15 EP EP13721386.4A patent/EP2814500B1/en active Active
- 2013-02-15 ES ES13721386T patent/ES2781773T3/es active Active
- 2013-02-15 HK HK15102492.2A patent/HK1202051A1/xx unknown
- 2013-02-15 EA EA201790862A patent/EA035931B1/ru unknown
- 2013-02-15 CN CN201380019578.5A patent/CN104271148A/zh active Pending
- 2013-02-15 AU AU2013220079A patent/AU2013220079B2/en active Active
- 2013-02-15 CN CN201811569705.XA patent/CN110075283A/zh active Pending
- 2013-02-15 JP JP2014557135A patent/JP6692602B2/ja active Active
- 2013-02-15 SG SG11201404943PA patent/SG11201404943PA/en unknown
- 2013-02-15 EA EA201491524A patent/EA028087B1/ru unknown
- 2013-02-15 SG SG10201609500QA patent/SG10201609500QA/en unknown
- 2013-02-15 CA CA2864432A patent/CA2864432A1/en not_active Abandoned
- 2013-02-15 CN CN201811569743.5A patent/CN110075284A/zh active Pending
- 2013-02-15 BR BR112014020304A patent/BR112014020304A8/pt not_active Application Discontinuation
- 2013-02-15 MX MX2014009900A patent/MX2014009900A/es unknown
- 2013-02-15 NZ NZ628851A patent/NZ628851A/en unknown
- 2013-02-15 NZ NZ722352A patent/NZ722352A/en unknown
- 2013-02-15 WO PCT/IB2013/000684 patent/WO2013121296A1/en not_active Ceased
- 2013-02-15 KR KR20147025631A patent/KR20150010699A/ko not_active Ceased
-
2014
- 2014-08-11 IL IL234056A patent/IL234056B/en active IP Right Grant
-
2017
- 2017-12-13 AU AU2017276218A patent/AU2017276218B2/en active Active
-
2018
- 2018-03-06 JP JP2018039593A patent/JP6716619B2/ja active Active
-
2020
- 2020-06-10 JP JP2020100620A patent/JP2020147591A/ja active Pending
-
2022
- 2022-09-16 JP JP2022147649A patent/JP2022184955A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018127458A5 (enExample) | ||
| JP2020147591A5 (enExample) | ||
| JP2017008046A5 (enExample) | ||
| Liu et al. | Zwitterionic polymer-protein conjugates reduce polymer-specific antibody response | |
| CN105189562B (zh) | Il-15异源二聚体蛋白及其用途 | |
| JP2022087255A5 (enExample) | ||
| JP2024045121A5 (enExample) | ||
| JP2019530440A5 (enExample) | ||
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| JP2016537340A5 (enExample) | ||
| JP2016507555A5 (enExample) | ||
| JP2005523946A5 (enExample) | ||
| JP2024156682A5 (enExample) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2018505893A5 (enExample) | ||
| CN101415403A (zh) | 药物制剂的固体口服剂形式及其制备方法 | |
| JP2022130681A (ja) | Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物 | |
| WO2019234694A3 (en) | Therapeutic methods using antibody drug conjugates (adcs) | |
| JP2015517492A5 (enExample) | ||
| JP2018530574A5 (enExample) | ||
| JP2019526244A5 (enExample) | ||
| Zhen-Gang et al. | Revisiting the immune landscape post spinal cord injury: More than black and white | |
| JPWO2021092081A5 (enExample) | ||
| JP2024538749A (ja) | 抗ｐｄ－ｌ１／ｉｌ－１０融合タンパク質を用いて疾患を処置する方法 | |
| US20160002312A1 (en) | Oral composition comprising a tnf antagonist and use thereof |